Search bioRxiv⌕ Search

Biology subjects

Mabilleau, G.

Publications and source records attributed to Mabilleau, G..

2 recordsLinked to original sources

Validation of Fourier transform infrared microspectroscopy for the evaluation of enzymatic cross-linking of bone collagen

Enzymatic cross-linking of the bone collagen is important to resist to crack growth and to increased flexural strength. In the present study, we proposed a new method for assessment of enzymatic cross-link based on FTIR microspectroscopy that takes into account secondary structure of type I collagen. Briefly, femurs were collected from sham or ovariectomized mice and subjected either to LC-MS or embedded in polymethylmethacrylate, cut and analyzed by FTIR microspectroscopy. FTIR acquisition were recorded before and after UV exposure or acid treatment. In addition, femurs from a second animal study were used to compare gene expression of Plod2 and Lox enzymes and enzymatic cross-links determined by FTIR microspectroscopy. We evidenced here that intensities and areas of subbands located at [~]1660 cm-1, [~]1680 cm-1 and [~]1690 cm-1 were positively and significantly associated with the concentration of pyridinoline (PYD), deoxypyridinoline (DPD) or immature dihydroxylysinonorleucine (DHLNL) / hydroxylysinonorleucine (HLNL) cross-links. Seventy-two hours exposure to UV light significantly reduced by [~]86% and [~]89% the intensity and area of the [~]1660 cm-1 subband. Similarly, 24 hours of acid treatment significantly reduced by 78% and 76% the intensity and area of the [~]1690 cm-1 subband. Plod2 and Lox expression were also positively associated to the signal of the [~]1660 cm-1 and [~]1690 cm-1 subbands. In conclusion, our study provided a new method for decomposing the amide I envelope of bone section that positively correlates with PYD and immature collagen cross-links. This method allows for investigation of tissue distribution of enzymatic cross-links in bone section.

biochemistry↗

Development of a first-in-class unimolecular dual GIP/GLP-2 analogue, GL-0001, for the treatment of bone fragility

Due to ageing of the population, bone frailty is dramatically increasing worldwide. Although some therapeutic options exist, they do not fully protect or prevent against the occurrence of new fractures. All current drugs approved for the treatment of bone fragility target bone mass. However, bone resistance to fracture is not solely due to bone mass but relies also on bone ECM material properties, i.e. the quality of the bone matrix component. Here, we introduce the first-in-class unimolecular dual GIP/GLP-2 analogues, GL-0001, that activate simultaneously the glucose-dependent insulinotropic polypeptide receptor (GIPr) and the glucagon-like peptide-2 receptor (GLP-2r). GL-0001 acts synergistically through a cAMP-LOX pathway to enhance collagen maturity. Furthermore, in mice with ovariectomy-induced bone fragility, GL-0001 prevented excess trabecular bone degradation at the appendicular skeleton and also enhanced bone ECM material properties through reduction of the degree of mineralization and augmentation in enzymatic collagen crosslinking. These results demonstrate that targeting bone ECM material properties is a viable option to enhance bone strength and opens an innovative pathway for the treatment of patients suffering of bone fragility.

pharmacology and toxicology↗